Almirall’s net sales growth in 2024 was 10.2% YoY (total of €985.7 MM) with EBITDA growth of 10.6% YoY (total of €192.6 MM) – surpassing guidance for the year with all key growth drivers delivering double digit growth.
- Company revenue growth continues to be driven by the strong performance of the European Dermatology business (+22.5% YoY, total sales of €484.1 MM), specifically biologics.
- Ebglyss® achieved 34% growth in Q4 compared to Q3, delivering a total of €33.2 MM sales in 2024, mainly in Germany. The product is now available in 11 markets across Europe and continues to receive very positive feedback from dermatologists.
- Ilumetri® continued its very strong growth trajectory with 25.5% sales increase YoY, delivering sales of €208.8 MM – based on continued market expansion and taking a higher share from competition.
Strong performance of Almirall´s broad dermatology portfolio: Wynzora® grew 53.3% YoY (total of €25.9 MM), and Klisyri® grew 17.8% YoY (total of €24.5 MM). Sustained solid growth of the medical dermatology portfolio overall: 17.8% (total of €548.1 MM). - Promising pipeline progress driven by Almirall’s sustained investment in R&D at 12.6% of net sales. Achieved milestones include the approval of the large field supplementary NDA for Klisyri® in the US, and the completion of the decentralized procedure for Efinaconazole in Europe. Several phase 1 studies are ongoing, and the rights for several early-stage assets were acquired.
- Guidance for 2025: Net Sales growth of 10%-13% and Total EBITDA between €220 MM and €240 MM.
Almirall SA was founded in 1944 in Spain and dedicated to medical dermatology. In 1979, the company launched gastroprokinetic clebopride in Spain, the first product from the company’s internal R&D team. In 1984, the business launched antacid product, almagate, in Spain, as well as anti-inflammatory piketoprofen in 1985 and antihistamine ebastine and cinitapride in 1985. In the same year, Almirall opened its first subsidiary, based in Belgium. In 1992 the company launched aceclofenac and a year later opened its second foreign subsidiary, in Portugal.
The company’s new headquarters were opened in Barcelona (Spain), in 1994. In 1997 Almirall and Prodesfarma merged their interests.
In 2023, the company generated total revenues of €898.8 million and was the leading European company in medical dermatology.
With approximately 1,904 employees (2023), it has a direct presence in 20 countries through its 15 subsidiaries in Europe and the USA.
